Rahul Singhvi

Dr. Rahul Singhvi is an Independent Director at Kairos Pharma Ltd., an Independent Director at Codexis, Inc., a Chief Executive Officer at Resilience Biotechnologies, Inc., a Chief Executive Officer at Swiftscale Biologics, Inc., a Managing Partner at Axella Solutions LLC and a President, Secretary, Treasurer & Director at Axella Biosciences, Inc. He is on the Board of Directors at Kairos Pharma Ltd., Tag1 Consulting, Inc., Codexis, Inc., Stratus Therapeutics, Inc., Axella Biosciences, Inc. and Keck Graduate Institute of Applied Life Sciences.
Dr. Singhvi was previously employed as a CO-Chief Executive Officer & Director by National Resilience, Inc., a President by Ring Therapeutics, Inc., an Operating Partner by Flagship Pioneering, Inc., a Chief Operating Officer by Takeda Pharmaceutical Co., Ltd., a Lead Independent Director by ImmunoCellular Therapeutics Ltd., a President & Chief Executive Officer by Novavax, Inc., a Director-Manufacturing Division by Merck & Co., Inc., a Member by Bill, Hillary & Chelsea Clinton Foundation, a Managing Partner by Caliber Biotherapeutics LLC, a Partner by Flagship Pioneering, Inc., a Chief Operating Officer by Magnum Hunter Resources, Inc., and a Chief Operating Officer by Takeda Vaccines, Inc. He also served on the board at NewGen BioPharma Corp.
/Old/, Univercells SA and Valor Biotherapeutics LLC.
He received his undergraduate degree from Indian Institute of Technology Kanpur, a graduate degree from Massachusetts Institute of Technology, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from Massachusetts Institute of Technology.